President & Managing Director
Gaby Murphy is the Managing Director and General Manager of EMD Serono's Canadian operations, where he works to ensure patients across Canada can benefit from the organization's innovative therapies in oncology, neurodegenerative diseases, fertility, and endocrinology.Gaby's expertise comes from more than 20 years of leadership experience in biopharmaceuticals, with significant knowledge in multiple sclerosis (MS) therapies. Earlier in his career, at Teva Pharmaceuticals, he launched the MS drug Copaxone. He first joined EMD Serono as National Sales Director in 2000 and for the next six years, helped to grow the organization's MS portfolio. In 2007, he moved to Novartis Canada, where he built the portfolios of several therapeutic areas, including cardiovascular and neurodegenerative diseases. Between 2009 and 2012, Gaby launched Novartis's MS unit, in particular, GILENYA (fingolimod) and EXTAVIA (interferon beta-1b) brands. His work as Novartis's Regional Neuroscience Head (Latin America and Canada), starting in 2012, saw Gaby championing treatments for MS, Parkinson's and Alzheimer's diseases. After working as the Business Lead, Virology with Bristol Myers Squibb, he rejoined EMD Serono in 2015. Gaby quickly re-established himself among the executive team, as the Head of the Neurodegenerative Diseases Business Unit. He took on his current role leading the Canadian business in November 2015.Gaby holds a Bachelor of Science degree (Biology), with a minor in Economics, from the Université du Québec à Montréal.
Laura is responsible for providing strategic legal support and compliance oversight for all business and functional units of EMD Serono, Canada. She is also the organization's Privacy Officer.Prior to joining EMD Serono in 2010, she spent three years in private practice at one of Canada's national law firms. Laura also provided legal expertise during a 10-year span in the corporate legal department of RBC Royal Bank, another highly regulated industry.Laura holds both Canadian and US Law degrees from the University of Windsor and a Bachelor of Commerce degree (McMaster University).
Khalid Sabihuddin brings 16 years of international operations and management experience in hospital, pharmaceuticals, and research environments to his role as Controller for EMD Serono's Canadian operations.In this position, Khalid plays an integral part in financial oversight for the organization. He also serves as a trusted advisor to and representative of the Managing Director.In previous roles, Khalid acted as Manager, Business Operations and Program Lead, HUB, with St. Michael's Hospital (Toronto); concurrently, he provided strategic and operational guidance as a consultant with Sidra Medical and Research Center in Doha, Qatar. He previously acted as the Research Ethics Coordinator, also at St. Michael's Hospital. Prior to this, Khalid gained clinical experience as a Research Coordinator with Allied Research International, and as an Interim Project Manager with the Association of International Physicians and Surgeons of Ontario (AIPSO).Khalid holds a Master of Business Administration degree (Finance and Marketing) from the University of Liverpool, a diploma in Clinical Research from Humber College, and a Bachelor of Science degree in Human Biology, Bioethics, and Environmental Biology from the University of Toronto.
Head of Operational Excellence
As Head of Operational Excellence, Erin Murphy puts her 16 years of experience in pharmaceutical marketing, sales, and customer engagement to good use in shaping the culture of EMD Serono's Canadian business. As a member of the leadership team, she is responsible for ensuring that all essential services from across the company work together to deliver industry leading value-added products and devices to support more patients across Canada.Before joining EMD Serono in 2015, Erin held increasingly senior sales and marketing roles with several global pharmaceutical companies. Most recently, as a National Sales Director at AstraZeneca Canada, she drove the market uptake of diabetes brands FORXIGA (dapagliflozin), ONGLYZA (saxagliptin), and KOMBOGLYZE (saxagliptin + metformin). Prior to this, she led marketing teams that achieved major growth milestones for a number of brands across an array of lifecycle phases — including AstraZeneca's SEROQUEL/SEROQUEL XR (quetiapine), SYMBICORT (budesonide + formoterol) and VIMOVO (naproxen + esomeprazole magnesium). She also excelled as a Product Manager for Leo Pharma's FUCIDIN (fucidic acid) portfolio and SELEXID (pivmecillinam).Erin holds a Bachelor of Science degree in Life Sciences and a Bachelor of Physical & Health Education degree from Queen's University (Kingston, Ontario).
Director, Market Access & Governmental Relations
Norm oversees government and payer strategies to improve patient access and achieve optimal reimbursement for our products. He has led patient advocacy campaigns to achieve public coverage of IVF and demonstrated the value of adherence to public payers.Previously, Norm led the Public Affairs function at various companies in the diagnostics and telecommunications industries. He began his career as a Health Policy Analyst/Strategist.Norm has a degree in Political Science (University of Waterloo), a post-graduate diploma in Public Relations (Humber College), and a Master Certificate in Marketing Communications (Schulich School of Business). He has also studied European politics at the Institut d'études politiques, Grenoble, France.In 2014, Norm received the President's THRIVE award, for living the patient-focused vision and values of the company.
Head of Regulatory and Scientific Affairs
As a seasoned regulatory affairs executive with over 18 years of experience in the pharmaceutical industry, Louise Blythe brings a wealth of expertise to her work with EMD Serono.Louise joined EMD Serono in 2016 as Head of Regulatory and Scientific Affairs. In this role, she provides overall leadership and direction to Regulatory Affairs for EMD Serono's full line of investigational and marketed products and devices in Canada. As a member of the local Leadership Team, Louise provides representation for Regulatory Affairs, Drug Safety (Pharmacovigilance) and Quality Operations.Prior to joining EMD Serono, Louise served as Director of Regulatory Affairs, Quality Assurance & Drug Safety at Forest Laboratories Canada, where she was instrumental in establishing Forest Laboratories' Canadian subsidiary and building the Regulatory and Quality Assurance department. She has also held various positions within Regulatory Affairs at AstraZeneca Canada, including Head of Strategic Product Development & Lifecycle Management, and was the Vice President, Global Regulatory Affairs at Cipher Pharmaceuticals.Louise holds a Master of Science degree in Pharmacology from the University of Toronto and a Bachelor of Science degree (with honours) from Queen's University (Kingston, Ontario).
Commercial Director, Xalkori & New Business
Russ Burrell has over 20 years experience in biopharmaceutical marketing, sales, and business and product development.Russ joined Serono in 1997 in Fertility and has worked in MS, Endocrinology, Dermatology, oncology and business development, where Russ was responsible for the five-year distribution and promotion agreement with Ipsen for SOMATULINE AUTOGEL (lanreotide).Previous leadership roles within EMD Serono include: Director of Marketing, Neurology (2000–2003); Business Unit Director, Dermatology & Metabolic Endocrinology (2003–2005); and Therapeutic Area Director, Dermatology (2005–2009). Prior to EMD Serono, Russ worked with A.C. Neilsen, Ortho Pharmaceuticals, Ortho-McNeil, and Janssen Ortho.In his current role as Commercial Director, XALKORI & New Business, Russ leads the EMD team supporting XALKORI (crizotinib) — through a partnership with Pfizer Canada. He is also responsible for new business development and is leading the planning to bring Avelumab to Canada for EMD.
Business Unit Head, Neurology
Neurology Business Unit Head Michael Milloy has 20 years' experience in the pharmaceutical industry, and is responsible for EMD Serono's flagship multiple sclerosis (MS) brand REBIF. He is also providing leadership to the cross-functional team that will bring Cladribine to Canadian MS patients.Prior to joining EMD, Michael was most recently the Head of Neurology Operations at Biogen Canada. While there, he specifically served as a member of the Global Strategy team and led the launch of several successful pharmaceuticals, drastically improving sales of existing products in Canada. Michael is a known team leader, specializing in managing high performance sales and marketing teams, and valuing an entrepreneurial atmosphere that challenges teams to drive their professional success.In addition to obtaining Commercial Education at Kellogg School of Management, Michael holds Bachelor degrees in Arts, and in Science, and a Master of Business Administration degree.
Business Unit Head, Fertility and Endocrinology
Hugo provides leadership to support the strategy and activities of Fertility and Endocrinology. Working closely with his team of sales and marketing professionals, he ensures the business unit has the instruments to continue achieving and maintaining success in all of our territories.
Prior to joining EMD Serono in September 2016, Hugo was the Associate Director of Marketing for Gilead Sciences Canada Inc., where he provided strategic direction and tactical planning for the Hepatitis C business unit and was responsible for launching two major award-winning brands in Canada for Hepatitis C and leading sales in HIV. In addition to his more recent experience, Hugo brings over 18 years of sales and marketing experience in the bio-pharmaceutical industry, where he has worked in a breadth of roles for Janssen-Ortho/Ortho Biotech and AstraZeneca. In addition to Virology, Hugo has extensive commercial involvement in more than 12 different therapeutic areas in a variety of markets, including Cardiology, CNS, Oncology, and Dermatology. Supplementing his commercial expertise, Hugo has broad experiences in people and brand life cycle management, deploying innovative initiatives to establish franchise vision and identity, commercial operations, key account management, as well as talent development and succession planning.
Hugo is fully bilingual in English and French, and holds Bachelor of Science degrees from McGill University in Microbiology/Immunology, as well as in Psychology.